Stock info Astrazeneca | Filter  Basic-Info

Stock: Astrazeneca (UK large caps), ISIN: GB0009895292

Last Price 9990.00 Max Price 13158.00
Min Price 9501.00 1 Year return -10.95
Avg. Target 0.00 Expected Return -100.00 %
Sector Health Care Subsector Pharmaceuticals
Sell 0 Rating
Hold 0 Concensus
Buy 0
Annual report 2012

Astrazeneca is one of the world's leading pharmaceutical companies. Astrazeneca provides medicines designed to fight disease in important areas of medical need: cancer, cardiovascular, gastrointestinal, infections, neurosciences and respiratory. Astrazeneca’s stocks are traded in London and the company is a component of the FTSE 100-index (ISIN: GB0009895292/ Symbol: AZN).

Loading...

Contact info:Street: 2 Kingdom StreetZip Code: London W2 City: LondonCountry: Great BritainPhone: 44 20 7604 8122Email: IR@astrazeneca.comWebsite: www.astrazeneca.co.uk

Sector Review Astrazeneca

Loading...
Year Turnover Total sector Market share
2019 24,384 615,634 3.96 %
2020 26,617 638,070 4.17 %
2021 37,417 727,968 5.14 %
2022 44,351 787,273 5.63 %
2023 0 0 0.00 %

Advice Astrazeneca

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
November 05, 2023 JP Morgan Astrazeneca Buy 14000.00 21.13 %
September 26, 2023 Jefferies & Co. Astrazeneca Buy 13000.00 8.48 %
September 26, 2023 Morgan Stanley Astrazeneca Buy 12900.00 7.77 %
July 14, 2023 UBS Astrazeneca Buy 13000.00 7.09 %
July 14, 2023 HSBC Astrazeneca Buy 13250.00 8.85 %
July 14, 2023 Morgan Stanley Astrazeneca Buy 12600.00 4.14 %
July 05, 2023 Jefferies & Co. Astrazeneca Buy 10500.00 -14.48 %
April 13, 2023 Morgan Stanley Astrazeneca Buy 13200.00 18.88 %
March 24, 2023 Berenberg Astrazeneca Buy 12400.00 15.90 %
March 11, 2023 UBS Astrazeneca Hold 11900.00 14.32 %
February 09, 2023 Deutsche Bank Astrazeneca Buy 13000.00 24.44 %
January 21, 2023 Stifel Astrazeneca Buy 12800.00 15.22 %
January 18, 2023 Berenberg Astrazeneca Buy 12600.00 13.87 %
January 06, 2023 Credit Suisse Astrazeneca Hold 11800.00 8.98 %
January 06, 2023 Morgan Stanley Astrazeneca Buy 12500.00 14.08 %
January 05, 2023 Jefferies & Co. Astrazeneca Buy 10800.00 0.56 %
January 03, 2023 JP Morgan Astrazeneca Buy 13500.00 22.70 %
December 29, 2022 Barclays Astrazeneca Buy 12500.00 16.51 %
November 21, 2022 Citigroup Astrazeneca Buy 14000.00 27.81 %
October 20, 2022 Berenberg Astrazeneca Buy 11800.00 4.49 %
October 10, 2022 JP Morgan Astrazeneca Buy 12500.00 11.95 %
October 08, 2022 Credit Suisse Astrazeneca Hold 11000.00 -0.05 %
September 15, 2022 Credit Suisse Astrazeneca Hold
September 10, 2022 Deutsche Bank Astrazeneca Buy 120000.00 91.08 %
August 05, 2022 Barclays Astrazeneca Buy 12500.00 11.23 %
July 29, 2022 JP Morgan Astrazeneca Buy 12500.00 11.54 %
June 13, 2022 UBS Astrazeneca Hold 10100.00 -15.96 %
May 18, 2022 Kepler Capital Markets Astrazeneca Hold 10500.00 -13.56 %
May 17, 2022 Societe Generale Astrazeneca Buy 15300.00 21.50 %
April 26, 2022 Barclays Astrazeneca Buy 12000.00 -1.55 %
April 26, 2022 Jefferies & Co. Astrazeneca Buy 9500.00 -28.27 %
April 26, 2022 Cowen and Company Astrazeneca Buy 12190.00 0.21 %
April 25, 2022 Morgan Stanley Astrazeneca Buy 11100.00 -9.78 %
April 07, 2022 JP Morgan Astrazeneca Buy 12000.00 6.30 %
February 16, 2022 Jefferies & Co. Astrazeneca Buy 8800.00 -30.89 %
January 25, 2022 Liberum Astrazeneca Buy 9690.00 -10.53 %
December 16, 2021 Morgan Stanley Astrazeneca Buy 10200.00 -11.76 %
December 10, 2021 Berenberg Astrazeneca Buy 10000.00 -11.78 %
December 07, 2021 Jefferies & Co. Astrazeneca Buy 9100.00 -22.84 %
November 12, 2021 KBC Securities Astrazeneca Buy 9500.00 -17.45 %



News Astrazeneca

Analysts anticipate for 2024 on revenue increase Astrazeneca, high dividend yield

Tomorrow the English Astrazeneca will publish its past quarters figures. Over the current book year the company from Cambridge's total revenue could be around 52.34 billion GBp (consensus estimates). The expected revenue would be a record for the company. This...

AstraZeneca signs deal to supply Canada 100k doses of COVID antibody therapy Evusheld

. AstraZeneca (NASDAQ:AZN) inked a conditional agreement with Canada to supply 100K doses of its antibody therapy Evusheld for the prevention (pre-exposure prophylaxis) of COVID-19. The antibody therapy is currently under review by Health Canada for use...

Analysts expect revenue increase Astrazeneca

Tomorrow the English Astrazeneca will publish its past quarter figures. Over the current book year the company from Cambridge's total revenue could be around 43.11 billion GBp (consensus estimates). This is hugely more than 2021's revenue of 37.42 billion GBp....

AstraZeneca teams up with Scorpion Therapeutics to develop cancer treatments

AstraZeneca (NASDAQ:AZN) collaborates with Scorpion Therapeutics to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment. Under terms of the agreement,...

AstraZeneca, Oxford start work on Omicron-specific COVID vaccine

Researchers at AstraZeneca (AZN) and Oxford University have begun work on developing a COVID-19 vaccine that would specifically target the Omicron variant, the Financial Times reports. An Oxford official told the newspaper that the university and company...

Annual reports Astrazeneca

2017 2018 2019 2020 2021

Profile Astrazeneca

Astrazeneca

(GB0009895292)/ AZN

The past year yielded positive returns for Astrazeneca investors

The stock lost over the past 12 months at around 2 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 50 percent. Astrazeneca's revenues between 2011 and 2015 were relatively steady and moved between 1721,32 billion GBp and 1676,49 billion GBp. Astrazeneca's net results between 2011 and 2015 were quite unstable and moved between 563,16 billion GBp and 283,62 billion GBp.

Astrazeneca has it' headquarter based in London. Astrazeneca is mostly active in the pharmaceutical sector. The past 10 years the (international) industry gained at around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-2016) there is a minus of 75 percent.

Over the past 5 years the English company paid out dividends. On average Astrazeneca's dividend yield over the past 5 years was around 1008,36 percent annually. Over the period 2011-2015 Astrazeneca raised it's dividends per share each year. So because of the yearly raised dividends per share Astrazeneca is a kind of dividend aristocrat.

Astrazeneca' balance mostly financed with equity

At the end of 2015 the pharmaceutical company's balance sheet was worth 4079,53 billion GBp. At the end of 2015 the total debt positon equaled 2824,95 billion GBp. This is around 69,25 percent of the total balance sheet. At the end of 2015 the pharmaceutical company's stock was traded with a price/earnings-ratio 20. So the stock' value was 20 times the 2015' earnings per share. We could say that based on her price/earnings-ratio and dividend yield the English stock can be seen as a value stock.

At the end of 2015 the English company's market capitalization equaled around 5835,26 billion GBp. At the end of 2015 around 1,26 billion stocks were listed.

All of Astrazeneca's annual reports are stored here. More information about Astrazeneca can be found it's website. .


Results Astrazeneca

Results
2015
2016
2017
2018
2019
2020
Revenue
24,708
23,002
22,465
22,090
24,384
26,617
Costs
21,883
19,503
19,464
19,935
23,049
23,421
Profit
2,825
3,499
3,001
2,155
1,335
3,196
Margin of profit
11.43
15.21
13.36
9.76
5.47
12.01
ROI
15.28
23.56
20.06
17.28
10.17
20.46

Balance Astrazeneca

Balance
2015
2016
2017
2018
2019
2020
Equity
18,490
14,854
14,960
12,468
13,127
15,622
Debt
41,566
47,672
48,394
48,183
48,250
51,107
Total assets
60,056
62,526
63,354
60,651
61,377
66,729
Solvency
30.79
23.76
23.61
20.56
21.39
23.41
Cash
6,853
5,902
4,554
5,680
6,218
7,992
Cashflow
3,324
4,145
3,578
2,618
2,969
4,799
Employees
0
0
0
0
0
Revenue per employee
0.0
0.0
0.0
0.0
0.0
Cashflow / Debt
0.08
0.09
0.07
0.05
0.06
0.09

Details Astrazeneca

Details
2016
2017
2018
2019
2020
Price
4616.50
4437.50
5121.00
5873.00
7607.00
Eps
2.76
2.37
1.70
1.03
2.43
Price/earnings-ratio
1672.64
1872.36
3012.35
5701.94
4111.11
Dividend
2.70
2.74
2.75
2.89
2.83
Dividend %
0.06 %
0.06 %
0.05 %
0.05 %
0.03 %
Payout %
0.98
1.16
1.62
2.81
1.16
Book value
11.74
11.81
9.84
10.00
11.90
Market to book
0.0
0.0
0.0
0.0
Cashflow per stock
3.28
2.83
2.07
2.26
3.66
Stocks
1,265
1,266
1,267
1,312
1,313
Market Cap
5.840.931.62
5.618.858.39
6.488.511.84
7.706.198.22
13.113.573.30

Dividend Astrazeneca


Price info Astrazeneca

Date
Price
13 Nov 2024
9990.00
08 Nov 2024
9725.00
05 Nov 2024
11042.00
31 Oct 2024
11206.00
29 Oct 2024
11628.00
23 Oct 2024
11864.00
19 Oct 2024
11946.00
16 Oct 2024
12024.00
14 Oct 2024
11936.00
05 Oct 2024
11738.00
02 Oct 2024
11800.00
27 Sep 2024
11720.00
20 Sep 2024
11898.00
17 Sep 2024
12016.00
13 Sep 2024
12050.00
28 Aug 2024
13158.00
26 Aug 2024
13076.00
23 Aug 2024
13018.00
11 Aug 2024
12700.00
07 Aug 2024
12690.00
05 Aug 2024
12458.00
01 Aug 2024
12368.00
30 Jul 2024
12364.00
26 Jul 2024
12060.00
23 Jul 2024
12260.00
16 Jul 2024
12104.00
10 Jul 2024
12078.00
09 Jul 2024
12044.00
04 Jul 2024
12020.00
02 Jul 2024
12550.00